ReviewChinese medicine2022
Key quality factors for Chinese herbal medicines entering the EU market.
Review in Chinese medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Heavy metals and pesticides in medicinal plants: environmental sources, plant responses, and human health risk assessment.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026Review
- Article
- Establishing traditional Chinese medicine in Europe.Chinese herbal medicines · 2025Article
- Recent advances in self-targeting natural product-based nanomedicines.Journal of nanobiotechnology · 2025Review
- The herbal pharmacopoeia of Ecuador: a national model for integrating traditional knowledge and biodiscovery.Frontiers in pharmacology · 2025Article
- Alcohol in Daily Products: Health Risks, Cultural Considerations, and Economic Impacts.Risk management and healthcare policy · 2025Review
- Traditional Chinese herbal medicine in European Union: State of art, challenges, and future perspectives focusing on Italian market.Chinese herbal medicines · 2025Review
- Progress in the application of hyperspectral imaging technology in quality detection and in the modernization of Chinese herbal medicines.Frontiers in chemistry · 2025Review
- Factors associated with the export of traditional Chinese medicinal products: A stochastic frontier analysis.PloS one · 2025Article
- Effect of Particle Size on Physical Properties, Dissolution, In Vitro Antioxidant Activity, and In Vivo Hepatoprotective Properties ofPharmaceutics · 2024Article
- Astragali radix (Huangqi): a time-honored nourishing herbal medicine.Chinese medicine · 2024Review
- Evaluation of comparative chemical profiling and bioactivities of medicinal and non-medicinal parts ofHeliyon · 2024Article
- An Acupuncture Protocol for the Treatment of Erectile Dysfunction: A Delphi Process.Complementary medicine research · 2024Article
- Crebanine induces ROS-dependent apoptosis in human hepatocellular carcinoma cellsFrontiers in pharmacology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Chinese herbal medicines (CHMs) have unique advantages in the prevention and treatment of diseases, which are widely recognized in the world. More and more CHMs are becoming increasingly popular in the international markets. However, the quality control of CHMs is a significant issue for their acceptance and recognition in the international market. This review mainly focuses on the quality requirements for CHMs to enter the European Union (EU) market. Both Chinese and European regulations and quality controls are compared. Firstly, the EU medicinal regulatory system and relevant regulations were reviewed. Secondly, the key factors of the quality control of CHMs, including Chinese herbal drugs, extracts and products were compared with those of European herbal medicines in the EU market. Subsequently, three main registration routes for herbal medicinal products including Chinese herbal medicinal products entering the EU were introduced. Furthermore, the legal status of traditional Chinese medicine granules in the EU was also discussed. Through the comparison of the key quality factors for CHMs in China and the EU, the similarities and differences in terms of quality requirements and regulations are addressed, which provides a reference for the development of CHMs into the EU market.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.